Repligen targets approximately 30% adjusted EBITDA margin
RGEN•Repligen targets an adjusted EBITDA margin of about 30% while investing to support sustainable growth. BioLife is expected to add more than 5 cents in first-year accretion, with revenue projected at $114 million in 2026, and the outlook assumes an approximately 2% gene therapy headwind in fiscal 2026.
1. Margin and BioLife outlook
Repligen targets an adjusted EBITDA margin of about 30% while investing to support sustainable growth. The BioLife acquisition is still expected to deliver more than 5 cents of first-year accretion, with BioLife revenue projected at $114 million in 2026, up from $75 million in 2024. The outlook continues to assume an approximately 2% gene therapy headwind in fiscal 2026.




